口服R115866治疗中度到重度plaque-type牛皮癣。

文章的细节

引用

复制到剪贴板

Bovenschen HJ Verfaille CJ, Thissen CA,莫顿J, Steijlen点,van de Kerkhof电脑

口服R115866治疗中度到重度plaque-type牛皮癣。

J专科北京医学Venereol欧元。2007年9月,21(8):1038 - 46所示。

PubMed ID

17714122 (在PubMed

]

文摘

背景:R115866 (Rambazole)是新一代all-trans视黄酸代谢阻断剂,对视黄酸4-hydroxylase非常具体。药物减轻增生和规范分化的表皮在银屑病动物模型。摘要目的:探讨疗效、安全性和耐受性的系统性R115866中度到重度患者plaque-type牛皮癣。病人和方法:打开标签,单臂试验中,患者接受R115866, 1毫克/天8周,紧随其后的是一个免费治疗随访期2周。病人监控的有效性和安全性。结果:19例(intent-to-treat人口)和14完成整个治疗研究。两个病人停止由于缺乏有效性和三个由于不良事件。的治疗,26%的患者至少有银屑病面积减少50%严重程度指数(PASI)与基线相比。进一步提高观察两周随访期间结束时,47%的患者显示50%或更大的减少帕斯。动态数据显示,没有证据表明R115866或积累在等离子体视黄酸。 The most common adverse events were pruritus, xerosis, cheilitis and an increase in blood triglycerides. The majority of adverse events were mild to moderate. No deaths or serious adverse events were reported. CONCLUSION: Eight-week daily treatment with 1 mg R115866 resulted in a significant reduction in PASI from baseline to end of therapy. Additional improvement was seen after the 2-week follow-up period. The drug was well tolerated. R115866 merits further evaluation to optimize its clinical efficacy and safety profile in moderate to severe plaque-type psoriasis.

DrugBank数据引用了这篇文章

药物

Talarozole

药物靶点

药物	目标	类	生物	药理作用	行动
Talarozole	细胞色素P450 26 a1	蛋白质	人类	未知的	不可用	细节